Phase II randomized clinical trial of LC9018 concurrently used with radiation in the treatment of carcinoma of the uterine cervix. Its effect on tumor reduction and histology

The clinical efficacy of LC9018, a biological response modifier prepared from heat‐killed Lactobacillus casei YIT9018, used in combination with radiation was studied in a randomized controlled trial on 61 patients with carcinoma of the uterine cervix of Stage IIB or III. The combination therapy with...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1989-11, Vol.64 (9), p.1769-1776
Main Authors: Okawa, Tomohiko, Kita, Midori, Arai, Tatsuo, Iida, Kouyo, Dokiya, Takushi, Takegawa, Yoshihiro, Hirokawa, Yutaka, Yamazaki, Kazuto, Hashimoto, Shozo
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - adverse effects
Adjuvants, Immunologic - therapeutic use
Aged
Antineoplastic Agents
Bacterial Vaccines - therapeutic use
Biological and medical sciences
Combined Modality Therapy
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Drug Evaluation
Female
Humans
Lactobacillus casei - immunology
Leukocyte Count
Leukopenia - prevention & control
Medical sciences
Middle Aged
Neoplasm Staging
Pharmacology. Drug treatments
Prognosis
Radiotherapy Dosage
Statistics as Topic
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - radiotherapy
Uterine Cervical Neoplasms - therapy
Vaccines, Attenuated
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical efficacy of LC9018, a biological response modifier prepared from heat‐killed Lactobacillus casei YIT9018, used in combination with radiation was studied in a randomized controlled trial on 61 patients with carcinoma of the uterine cervix of Stage IIB or III. The combination therapy with LC9018 demonstrated a significant effect on tumor reduction, compared with radiation therapy alone, at the cumulative doses of 15‐Gy and 30‐Gy external irradiation (P < 0.05). Histologic study confirmed that LC9018 also enhanced the therapeutic effect of the irradiation. Moreover, LC9018 seemed to be useful in protecting the patients from leukopenia during radiotherapy. This study suggests that LC9018, when used in combination with radiotherapy, will be an effective adjuvant immunotherapeutic agent. More studies in a large series of patients will, however, be needed to establish its long‐term efficacy, safety, and effects on both prognosis and enhancing radiotherapy.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19891101)64:9<1769::AID-CNCR2820640902>3.0.CO;2-G